Biomea Fusion Raises $56 Million to Bring First Irreversible Menin Inhibitor into the Clinic and Advance Two Additional Irreversible Preclinical Programs
Biomea Fusion Raises $56 Million to Bring First Irreversible Menin Inhibitor into the Clinic and Advance Two Additional Irreversible Preclinical Programs
01/06/21, 4:04 PM
Location
redwood cityMoney raised
$56 million
Biomea Fusion, Inc., a precision oncology company dedicated to developing innovative medicines targeting genomically defined alterations in both hematologic and solid cancers, announced the closing of a $56 million Series A financing today. The syndicate is led by Cormorant Asset Management with participation from Boxer Capital of Tavistock Group, Janus Henderson Investors, Rock Springs Capital, RTW Investments, LP, Aisling Capital, Point Sur Investors, Logos Capital and Clifton Capital.
Company Info
Location
redwood city, california, united states
Additional Info
Biomea Fusion is a privately held precision medicine company with a mission to revolutionize drug development to create more effective therapies for cancer patients. The company was founded by a team of experienced drug developers to build a platform of irreversible inhibitors. Biomea Fusion has a development portfolio that targets specific gene mutations which occur in the DNA of patients that translate into key drivers of tumor growth. It is Biomea’s goal to move these potentially breakthrough medicines swiftly through the development process and deliver highly impactful treatments for patients in need. The lead program targets the protein-to-protein interaction between menin and the MLL complex for the treatment of various tumors. This program is currently in IND enabling studies and is planned to enter the clinic in the second half of 2021. For more information, please visit www.biomeafusion.com and follow us on LinkedIn.